Adaptive Servo-Ventilation Therapy Improves Long-Term Prognosis in Heart Failure Patients With Anemia and Sleep-Disordered Breathing
-
- Suzuki Satoshi
- Department of Cardiology and Hematology, Fukushima Medical University Department of Advanced Cardiac Therapeutics, Fukushima Medical University
-
- Yoshihisa Akiomi
- Department of Cardiology and Hematology, Fukushima Medical University Department of Advanced Cardiac Therapeutics, Fukushima Medical University
-
- Miyata Makiko
- Department of Cardiology and Hematology, Fukushima Medical University
-
- Sato Takamasa
- Department of Cardiology and Hematology, Fukushima Medical University
-
- Yamaki Takayoshi
- Department of Cardiology and Hematology, Fukushima Medical University
-
- Sugimoto Koichi
- Department of Cardiology and Hematology, Fukushima Medical University
-
- Kunii Hiroyuki
- Department of Cardiology and Hematology, Fukushima Medical University
-
- Nakazato Kazuhiko
- Department of Cardiology and Hematology, Fukushima Medical University
-
- Suzuki Hitoshi
- Department of Cardiology and Hematology, Fukushima Medical University
-
- Saitoh Shu-ichi
- Department of Cardiology and Hematology, Fukushima Medical University
-
- Takeishi Yasuchika
- Department of Cardiology and Hematology, Fukushima Medical University Department of Advanced Cardiac Therapeutics, Fukushima Medical University
この論文をさがす
抄録
Sleep disordered breathing (SDB) and anemia influences the progression of chronic heart failure (CHF). Adaptive servo-ventilation (ASV) is an effective therapeutic device for treatment of CHF, however, the impacts of ASV on CHF patients with or without anemia remain unclear.<br>A total of 139 patients with CHF and SDB were divided into two groups: those treated with ASV (n = 53) and without ASV (n = 86). All patients were prospectively followed after discharge with the endpoints of cardiac death or progressive heart failure requiring rehospitalization. There were 65 patients (47%) with anemia among all subjects. The apnea hypopnea index was improved, and plasma BNP and high sensitive C-reactive protein levels were decreased in both groups with and without anemia by ASV therapy. The Kaplan-Meier survival curve demonstrated that the cardiac event-free rate in patients with ASV was significantly higher than in those without ASV in the anemia group (P = 0.008). However, in the non-anemia group, the cardiac event-free rate was similarly high in patients both with and without ASV (P = 0.664). Multivariate Cox proportional hazard analysis demonstrated that ASV use was an independent predictor of cardiac events in the anemia group (P = 0.0308), but not in the non-anemia group.<br>ASV treatment for CHF and SDB has more favorable impacts in patients with anemia than in those without anemia.
収録刊行物
-
- International Heart Journal
-
International Heart Journal 55 (4), 342-349, 2014
一般社団法人 インターナショナル・ハート・ジャーナル刊行会